SUMMARY Cross-sectional and longitudinal studies have been carried out to determine the incidence and clinical significance of eosinophilia in patients taking penicillamine for rheumatoid arthritis. In a cross-sectional study of 204 patients eosinophilia was found with equal frequency during treatment with penicillamine, gold, and nonsteroidal anti-inflammatory drugs. A longitudinal study of 89 patients treated with penicillamine showed no consistent relationship between eosinophilia and adverse reactions to the drug. It is concluded that routine monitoring of eosinophil counts is unlikely to be of value in the management of patients taking penicillamine.
Eosinophilia is considered to be a frequent finding in patients with rheumatoid arthritis (RA).' It has been related to severe disease with nodules, extra-articular manifestations, and immunological changes,23 although not all studies support this view. 4 Davis and Hughes5 studied the relationship of eosinophilia to gold therapy and suggested that there was an important association between an eosinophilia and the development of adverse reactions, especially cutaneous. Their results imply that sequential eosinophil counts might be useful when monitoring gold therapy. In dosage ranged from 125 to 750 mg daily, in accordance with a flexible response-related regimen.9 Blood counts, including total white cell counts, were measured by a Coulter Counter Senior. Differential white cell counts and platelet counts were performed manually by standard laboratory methods."0 An eosinophilia was defined for the purposes of this study as a total eosinophil count of greater than 0-4 x 109/l.
Results
An eosinophilia was present in 12% of the 204 patients in the cross-sectional study. The eosinophil counts in these patients ranged from 041 to 1 *63 x 109/l. Eosinophilia was as common in patients taking nonsteroidal anti-inflammatory drugs alone as in patients taking gold or penicillamine in addition (Table 2) . A comparison of patients taking penicillamine with those taking nonsteroidal antiinflammatory drugs alone showed no significant differences either in the numbers of patients with an eosinophilia (X2 = 2-2, DF = 1, p>0.10) or in the eosinophil counts themselves (t = -0-33, p>0.10). The other groups of patients gave similar comparisons.
In the longitudinal study 47 patients out of 89 (53%) developed an eosinophilia on one or more occasions during penicillamine therapy. There were no differences in age or sex between those patients who developed an eosinophilia and those who did not, nor was there a difference in the number of patients who had previously received gold. Eighteen of the patients had an adverse reaction within 1 month of developing an eosinophilia, and details are given in Table 3 . Penicillamine therapy was continued unchanged in 5 patients, suspended and thereafter restarted at a lower dose in 12 patients, and stopped in only 1 patient. There was no indication that the development of an eosinophilia heralded the onset of a severe adverse reaction.
Discussion
Our results confirm that eosinophilia is common during penicillamine therapy. It occurs with equal frequency in patients taking gold or nonsteroidal anti-inflammatory drugs alone and is therefore not specific to penicillamine.
Eosinophilia occurred in association with adverse reactions in some patients included in the longitudinal study, but this was not invariable. Such adverse reactions were generally mild and the drug was continued or resumed after a suspension of treatment in all but one case.
The review of 25 patients who had stopped penicillamine (Table 1) showed that in 5 patients a serious adverse reaction was preceded by an eosinophilia. However, further analysis qualifies this finding. One of these patients had developed repeated episodes of eosinophilia over several years, including an episode prior to penicillamine therapy. Another patient developed eosinophilia in association with cutaneous vasculitis and high titres of circulating immune complexes, suggesting that a change in the disease process3 rather than a drug reaction was involved. We conclude that eosinophilia is common during penicillamine therapy and other forms of drug treatment for RA. There is no evidence that eosinophilia presages adverse reactions to penicillamine, and routine monitoring of eosinophil counts is unlikely to be of clinical value in the management of patients taking this drug. 
